Stocks ended higher today, with the Dow Jones Industrial Index
climbing to a five-year high, led by energy stocks as crude oil
pushed past $97 per barrel amid rising Mid-East tensions.
Healthcare and other defensive sectors also rose, in a sign some
market participants attributed to growing numbers of retail
investors getting back into the market.
Shares began today little changed after a measure of consumer
confidence fell to its lowest level in more than a year, offsetting
momentum supplied by earlier reports of another big rise in U.S.
housing prices during November. But the market moved higher as the
session progressed, with the S&P 500 set to finish its best
month since October 2011.
Better-than-expected earnings helped propel today's gains, with
) rising more than 11% after the refiner reported adjusted net
income of $1.88 per share, crushing analyst expectations by $0.70.
Quarterly revenue was flat at $34.7 billion.
Eli Lilly and Company (
) and Pfizer Inc. (
) underpinned gains in the healthcare sector, with LLY beating
Street estimates by $0.07 a share after reporting an $0.85 Q4
profit, with new products making up for revenue lost to patent
expirations and generic competition.
Consumer confidence plunged in January to its lowest level in
more than a year, reflecting higher Social Security taxes that left
most Americans with less take-home pay. The Thomson
Reuters/Conference Board consumer confidence index fell to a final
58.6 reading for January, down from a 66.7 score in December and
the lowest mark since November 2011.
Home prices in 20 major U.S. cities increased 5.5% in November,
marking their biggest jump in six years, according to the
Case-Shiller 20-city home price index.
Crude oil continued its rise in world commodities markets, with
the March contract ending $1.13 higher at $97.57 per barrel,
climbing as high as $97.82 after Egypt's defense chief warned that
political unrest could bring about the "collapse" of the state,
increasing pressure on President Mohamed Mursi.
Other commodities were mostly higher. February gold rose $7.50
to $1,660.60 per ounce while March silver added 42 cents to settle
at $31.20 per ounce. March copper rose 3 cents to $3.69 per pound.
March natural gas fell 5 cents to 43.26 per 1 million BTU.
Here's where the U.S. markets stood at the end of regular
Dow Jones Industrial Average up 0.52% to 13,954.42
S&P 500 up 0.51% to 1,507.84.
Nasdaq Composite Index down 0.02% to 3,153.66
Hang Seng Index down 0.07%
Shanghai China Composite Index up 0.53%
FTSE 100 Index up 0.71%
(+) SOMH, Agrees to a $64.4-million buyout by Lakeland Bancorp (
), with shareholders receiving either $12 a share in cash or 1.1962
shares of LBAI common stock for each share they currently own. LBAI
shares are lower today.
(+) IPAR, Reports 6.3% rise in 2012 net sale to a record $654.1
million, beating its prior guidance of $632 million due to
better-than-expected Q4 sales. IPAR will issue its Q4 results on
(+) SWIR, Selling its AirCard business to Netgear (
) for $138 million in cash plus another $6.5 million in assumed
liabilities. The company also said it is exploring alternatives to
return a portion of the proceeds to shareholders, pending approval
by the Toronto Stock Exchange. NTGR is lower today.
(+) PLXT, Raised to a Buy rating from a Hold at Wunderlich after
the company reports non-GAAP net income of $0.06 a share during Q4,
$0.05 better than estimates. Trails analyst forecasts for revenue,
generating $23.4 million in sales, $1.45 million under the analyst
(-) SANM, Fiscal Q1 profit misses by $0.05. Guides Q2 below
(-) VMW, Offers Q1 and FY13 revenue guidance trailing the Wall
Street consensus, triggering a slew of analyst downgrades. Also
cutting about 900 jobs. Q4 earnings of $0.81 a share beat by $0.03.
Revenues were in-line.
(-) OXF, Suspends Q4 cash distributions on its common and
subordinated units, citing a need to preserve liquidity.
(-) ANAC, Said its prospective treatment for toenail fungus
resulted in a "complete cure" during Phase III testing, but still
appears mostly inferior to a competing drug. Results from a second
Phase III study of tavaborole are due out in March.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.